Interferon alpha-2b biosimilar - Pharmaclon

Drug Profile

Interferon alpha-2b biosimilar - Pharmaclon

Alternative Names: Alfaron; Alfarona; Alpharona

Latest Information Update: 12 Jun 2015

Price : $50

At a glance

  • Originator Pharmaclon
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunomodulators; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia; Basal cell cancer; Chronic myeloid leukaemia; Conjunctivitis; Hairy cell leukaemia; Hepatitis B; Hepatitis C; Hepatitis D; Influenza virus infections; Lymphoma; Multiple sclerosis; Mycoplasma infections; Recurrent respiratory papillomatosis; Renal cancer; Severe acute respiratory syndrome; Squamous cell cancer; Thrombocytopenia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Dec 2014 Registered for Acute lymphoblastic leukaemia (In children, Recurrent) in Azerbaijan (Parenteral)
  • 30 Dec 2014 Registered for Basal cell cancer in Azerbaijan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top